How Often Do You Inject Ozempic for Weight Loss — and Why the Answer Is More Complicated Than You'd Expect

You've found Ozempic mentioned everywhere for weight loss, here's what's actually going on

Picture this: you've seen social media posts, maybe a magazine piece, about a weekly injection that helps people lose significant amounts of weight. The brand name that keeps appearing is Ozempic. You search for how often to use it, what dose you'd start on, whether you can get it privately. It feels like a reasonable place to start.

The confusion is understandable. Ozempic and Wegovy both contain semaglutide, made by Novo Nordisk. They work through the same mechanism, activating GLP-1 receptors in the gut and brain to reduce appetite and slow how quickly food leaves the stomach. But the UK Medicines and Healthcare products Regulatory Agency has licensed them for completely different purposes. Ozempic: type 2 diabetes. Wegovy: weight management. That licensing decision shapes who can be prescribed each medicine, what dose they receive, and through which clinical pathway.

If you're specifically looking for background on why Ozempic became so associated with weight loss in public conversation, that page explores the history in more detail. For now, the practical point is this: if a UK prescriber writes you Ozempic specifically so you can lose weight, they are prescribing it outside its licensed indication. That's legally permissible in medicine but carries implications for oversight, monitoring and what happens if something goes wrong. A well-run clinic won't do it routinely.

The weekly injection you may have read about for weight loss is Wegovy, and how often Wegovy is injected follows a structured schedule that is worth understanding in full before you begin treatment.

How the Wegovy injection schedule actually works, and why the slow start matters

Wegovy is given once a week, on the same day each week, as a subcutaneous injection under the skin. The schedule does not begin at the maintenance dose. It starts at 0.25 mg, a tolerability level whose job is to let your digestive system adjust gradually rather than to produce significant weight loss straight away. From there, a prescriber titrates the dose upward roughly every four weeks: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching the 2.4 mg maintenance dose around week 16 or 17.

In January 2026, the MHRA approved a higher 7.2 mg maintenance dose of semaglutide (Wegovy) following trial data showing average weight reductions of around 20.7% over 72 weeks at that level. A dedicated single-dose 7.2 mg pen was approved in April 2026. Titration toward 7.2 mg follows the same principle of gradual steps under clinical supervision.

The slow ramp-up is not optional or a marketing choice. It exists because semaglutide's most common side effects are gastrointestinal (nausea, loose stools, indigestion) and they are far more manageable when the dose builds over months rather than arriving all at once. Many people keep their pen in the fridge door alongside everyday items and find the weekly routine becomes unremarkable within a few weeks. The NHS semaglutide information explains the standard schedule and what to do if you miss a dose.

If you are curious how many injections are typically involved across a course of semaglutide treatment for weight loss, that page breaks down the numbers across the full titration period. For a plain-language explanation of how the injection itself works biologically, this page on the mechanism covers the GLP-1 pathway in plain language.

Choosing the right licensed treatment: Wegovy versus Mounjaro

Once you understand that Ozempic is not the appropriate prescription for weight loss, the practical question becomes which licensed medicine (Wegovy or Mounjaro (tirzepatide)) might suit you. Both are once-weekly subcutaneous injections. Both are prescription-only medicines that require a clinical assessment before a prescriber can lawfully issue them.

The differences are meaningful. Wegovy is a GLP-1 receptor agonist; Mounjaro is the only dual GIP and GLP-1 receptor agonist licensed in the UK, activating two gut-hormone pathways simultaneously. In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults living with obesity. Whether that difference is relevant to you depends on your health history, any other medicines you take, and factors only a prescriber can weigh.

For a clear comparison of the two options, our treatment overview sets out what each involves. If cost is part of your thinking, the Wegovy pricing page covers what private treatment typically costs and what drives the variation between providers.

A prescriber does not just pick the medicine with the biggest trial numbers. They look at your BMI, your weight-related health conditions, your medication history, and your preferences. That conversation is where treatment decisions belong.

Getting started: what a legitimate UK route looks like

Because Wegovy and Mounjaro are both prescription-only medicines, there is no legal route to either without a clinical assessment by a qualified prescriber. The MHRA's drug safety guidance consistently warns that purchasing injectable weight-loss medicines from sellers who supply them without a proper prescription and clinical review carries serious risks, counterfeit pens have been found in circulation, some containing incorrect substances.

A reputable online pharmacy will ask you to complete a health questionnaire, verify your identity and current weight, and have your responses reviewed by a real clinician before any prescription is issued. If you are also wondering where on the body semaglutide injections are given and how the technique works in practice, that page covers the recommended sites and what to expect. At nume, that review is done by a GPhC-registered Independent Prescriber, a named person reading your answers, not automated software running through a checklist. Prescriptions are only issued where treatment is clinically appropriate.

If you'd like to explore whether Wegovy or Mounjaro might be suitable for you, our prescribers are available seven days a week. Speak to our prescribers through a free consultation, no commitment, no hidden fees.